Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorpheniramine + dextromethorphan (Zinnia Life Sciences)
- Development stage
- Unknown
- Lead developer
- Zinnia Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ultrakof is an oral combination syrup containing the antihistamine chlorpheniramine maleate and the cough suppressant dextromethorphan hydrobromide. Developed by Zinnia Life Sciences, it is indicated for the temporary relief of dry, irritating coughs and associated allergic symptoms such as runny nose, sneezing, and watery eyes caused by the common cold, upper respiratory allergies, or hay fever. Chlorpheniramine acts as a competitive antagonist of histamine H1 receptors, reducing allergic responses, while dextromethorphan acts centrally on the cough center in the medulla oblongata to suppress the cough reflex.
- Brand names
- Ultrakof
- Other names
- chlorpheniramine maleate + dextromethorphan hydrobromidedextromethorphan + chlorpheniraminedextromethorphan hydrobromide + chlorpheniramine maleate
02
Targets
DAT (Dopamine plasma membrane transport protein)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)Nicotinic Acetylcholine ReceptorNET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)SIGMAR1 (Sigma non-opioid intracellular receptor 1)CaV (Voltage-gated calcium channel protein complex)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on chlorpheniramine + dextromethorphan (Zinnia Life Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorpheniramine + dextromethorphan (Zinnia Life Sciences).